Mural Oncology plc (NASDAQ:MURA) Short Interest Up 46.4% in March

Mural Oncology plc (NASDAQ:MURA) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 594,500 shares, an increase of 46.4% from the March 15th total of 406,100 shares. Currently, 3.9% of the shares of the stock are sold short. Based on an average daily volume of 278,000 shares, the days-to-cover ratio is currently 2.1 days.

Hedge Funds Weigh In On Mural Oncology

A number of large investors have recently bought and sold shares of MURA. FMR LLC raised its holdings in Mural Oncology by 124.7% during the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after buying an additional 11,423 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Mural Oncology during the fourth quarter valued at about $68,000. Two Sigma Advisers LP purchased a new stake in shares of Mural Oncology during the fourth quarter worth about $84,000. Bridgeway Capital Management LLC bought a new stake in shares of Mural Oncology in the fourth quarter worth about $94,000. Finally, Virtu Financial LLC purchased a new position in Mural Oncology during the 4th quarter valued at about $129,000. 80.21% of the stock is owned by hedge funds and other institutional investors.

Mural Oncology Stock Performance

Shares of MURA opened at $2.70 on Friday. Mural Oncology has a fifty-two week low of $0.95 and a fifty-two week high of $4.74. The firm has a market cap of $46.52 million, a price-to-earnings ratio of -0.30 and a beta of 5.28. The firm has a 50 day moving average price of $2.86 and a 200-day moving average price of $3.36.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same quarter last year, the firm posted ($3.57) EPS. As a group, equities research analysts predict that Mural Oncology will post -7.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

MURA has been the subject of several recent analyst reports. Jones Trading reissued a “hold” rating on shares of Mural Oncology in a report on Tuesday, March 25th. HC Wainwright decreased their price target on shares of Mural Oncology from $18.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, March 26th. Raymond James downgraded shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price objective for the company. in a report on Tuesday, March 25th. Finally, Morgan Stanley cut Mural Oncology from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, March 25th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $13.00.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.